No abstract

Background: In 1988 the US Food and Drug Administration permitted low dose methotrexate for the treatment of rheumatoid arthritis that would change the progression of the disease. Methotrexate is a folic acid antagonist and its systemic use causes numerous side effects; including hepatic toxicity. It would be preferable to deliver methotrexate by the topical route to reduce side-effects along with ease of administration and reduced dosing frequency. So, nanoparticle gel is a hopeful approach to treat rheumatoid arthritis. Objective: To develop a nanoparticles gel containing novel natural polymer-based methotrexate nanoparticles and evaluate its therapeutic potential on Complete Freund’s Adjuvant–Induced Arthritis rat model and compare it to methotrexate and dexamethasone gel. Result and Discussion: Methotrexate nanoparticles gel significantly reduced the percentage inhibition of oedema compared to methotrexate and Dexamethasone gel. The therapeutic activity of nanoparticles gel was found to be F3W2 ≥ F2W2 ≥ F1W2 ≥ F4W2 ≥ MTX gel. So, the optimized nanoparticle gel formulation F3W2 can be effective in treatment of rheumatoid arthritis. Materials and methods: The five batches methotrexate nanoparticles gel were prepared viz. F1W2, F2W2, F3W2, F4W2 and methotrexate gel for the topical application by using different concentrations of Carbopol 934 base and characterized for their evaluation parameters: Homogeneity, Grittiness, pH, Spread-ability, Viscosity determination, and Drug content studies. The arthritic potential of methotrexate-nanoparticles gel was evaluated by CoResult and Discussion: Methotrexate nanoparticles gel significantly reduced the percentage inhibition of oedema compared to methotrexate and Dexamethasone gel. The therapeutic activity of nanoparticles gel was found to be F3W2 ≥ F2W2 ≥ F1W2 ≥ F4W2 ≥ MTX gel. So, the optimized nanoparticle gel formulation F3W2 can be effective in treatment of rheumatoid arthritis.mplete Freund’s Adjuvant–Induced Arthritis rats model based on percent inhibition oedema and arthritic score. Conclusion: The developed novel nanoparticles gel formulation can be a promising alternative to existing methotrexate and Dexamethasone gel.

Solid lipid nanoparticles (SLN) are colloidal carrier systems providing controlled release profiles for many substances. These are interesting nanoparticulate delivery systems produced from solid lipids. Erythromycin-loaded SLN were prepared using glyceryl behenate as solid lipid by microemulsion technique and evaluated for particle size, zeta potential as well as entrapment efficiency of this lipophilic drug. The formulation was optimized using taguchi design L9 orthogonal array. The formulated SLNs were found to be relatively uniform in size (355.29 nm) with a negative zeta potential (−15.90 mV). The average drug entrapment efficiency and loading were 51.65%. The ultimate objective of the present study was to formulate erythromycin loaded solid lipid nanoparticulate (ESLN) gel and compare it with conventional gel of erythromycin with respect to ex-vivo release and primary skin irritation studies. ESLN gel produced significantly higher deposition of erythromycin in skin than conventional gel. Release mechanism was found to be a coupling of diffusion and erosion. The obtained results for primary skin irritation studies displayed no erythema or edema on intact rat skin. The SLN based gel described in this study elicited prolonged activity of upto 24 h.